The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1573
ISSUE 1573
June 3, 2019
Issue 1573
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
Risankizumab (Skyrizi) for Psoriasis
June 3, 2019 (Issue: 1573)
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi – Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist to
be approved for this indication; guselkumab (Tremfya)
and tildrakizumab (Ilumya) were approved earlier.
... more
- Tildrakizumab (Ilumya) – another IL-23 antagonist for psoriasis. Med Lett Drugs Ther 2019; 61:4.
- Guselkumab (Tremfya) for psoriasis. Med Lett Drugs Ther 2017; 59:179.
- Drugs for psoriasis. Med Lett Drugs Ther 2015; 57:81.
- E Sbidian et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12:CD011535.
- A Menter et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019; 80:1029.
- IM Haugh et al. Rizankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther 2018; 12:3879.
- KB Gordon et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392:650.
- K Reich et al. Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial. American Academy of Dermatology Annual Meeting, Washington, DC, March 1-5, 2019. Poster 10218.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1573
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian